FDA — authorised 26 April 2019
- Application: BLA125370
- Marketing authorisation holder: HUMAN GENOME SCIENCES INC.
- Indication: Efficacy
- Status: approved
🇺🇸 Lymphostat B in United States
FDA authorised Lymphostat B on 26 April 2019
Marketing authorisations
FDA — authorised 15 February 2023
- Application: BLA761043
- Marketing authorisation holder: GLAXOSMITHKLINE LLC
- Indication: Efficacy
- Status: approved
Lymphostat B in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Lymphostat B approved in United States?
Yes. FDA authorised it on 26 April 2019; FDA authorised it on 15 February 2023.
Who is the marketing authorisation holder for Lymphostat B in United States?
HUMAN GENOME SCIENCES INC. holds the US marketing authorisation.